The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vatiquinone for the treatment of children and ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of ...
A new study has revealed that patients who develop hyponatremia soon after starting thiazide diuretics face a higher risk of ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Friedreich's ataxia is a rare and life-shortening neuromuscular disorder that affects the central nervous system and the heart. With symptoms typically emerging in childhood or adolescence ...
We thank Michèl Willemsen and colleagues for their interest in the ATTeST trial of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia.1 The two doses studied in ...
The U.S. Food and Drug Administration (FDA) has accepted for filing PTC Therapeutics’ New Drug Application (NDA) for ...
5d
News Medical on MSNGene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
PTC Therapeutics (PTCT) announced that the U.S. Food and Drug Administration, FDA, has accepted for filing the New Drug Application, NDA, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results